6月21日据诺和诺德网站消息在芝加哥举行的美国糖尿病协会(ADA)科学会议上诺和诺德公布了针对非糖尿病肥胖症患者的3b期

智通财经
21 Jun
6月21日据诺和诺德网站消息在芝加哥举行的美国糖尿病协会(ADA)科学会议上诺和诺德公布了针对非糖尿病肥胖症患者的3b期STEPUP试验结果。数据显示在72周治疗期内与安慰剂相比更高剂量Wegovy(司美格鲁肽7.2mg)可使肥胖症患者平均减重21%其中三分之一受试者减重幅度达25%或更高。更高剂量Wegovy(7.2mg)的安全性和耐受性与2.4mg剂量一致。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10